spacer
home > ict > autumn 2017 > three-fold solution
PUBLICATIONS
International Clinical Trials

Three-Fold Solution

Astonishingly, the same four problems that delayed trial
start-ups 20 years ago are still doing so today; very little has
changed. Sponsors, CROs and investigator sites consistently
name redundant training and certification, budgeting
and contracting issues, vendor relations and scheduling
concerns as the top reasons that site activation can take
up to a year (1).

Certainly, these are not the only issues that cause stoppage.
Feasibility studies, regulatory matters and institutional
review board (IRB) approvals play their part, but the ‘big
four’ remain the same. However, stakeholders can embrace
a three-fold solution to speed up trial start dates, which
has the potential to slash site activation times to as little
as 30 days.

The ‘Big Four’

Before turning to the solution, having a clear
understanding of the problems preventing swift site
activation is important.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Sean Stanton is Senior Vice President Global Operations at Bioclinica Research Network. He has dedicated the last 25 years of his career to creating successful, high-performing research sites and, to date, has led the start-up of 25 trial sites, six inpatient hospitals and 19 outpatient clinics. More than 5,000 trials have been conducted at these sites, leading to over 50 drug approvals, and, in these, he directed recruitment for the screening of 2,000 to 6,000 patients annually. A sought-after industry expert, Sean has brought innovative thinking to research in all aspects of site practice, from purchasing and resourcing to the use of benchmarking and metrics in business planning to guide trial growth.
spacer
Sean Stanton
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

rfxcel Covers the Cost of EMVO Onboarding Fees

May 23, 2018 - San Ramon, CA – rfxcel Corporation, a technically certified Gateway Provider for the European Medicines Verification Organisation (EMVO) announced today that it will pay the cost of statutory fees payable to EMVO* for all manufacturers (Marketing Authorisation Holders, MAHs) which select rfxcel as their Gateway Provider before June 15th 2018.
More info >>

White Papers

Preparation of Pharmaceutical Samples for Metals Analysis

RSSL

There has been a lot of discussion regarding the methods of analysis for pharmaceutical products as we await the upcoming changes to both the EP and USP, relating to the analysis of metal impurities.
More info >>

 
Industry Events

On Helix 2018

10-11 July 2018, The Cambridge Building, Babraham Research Campus

ON Helix is a two-day event aimed at informing delegates of how to turn early stage inventions and ideas into innovative health treatments (new medicines, novel biomarkers, useful medical devices or improved medical practices).
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement